Design and Synthesis of Diaminotriazines as Anti-Tuberculosis DHFR Inhibitors
Arundhati C Lele1, Archana Raju1, M.K. Ray2, M.G.R. Rajan2 & Mariam S Degani1 Show affiliations
- Institute of Chemical Technology, India
- Bhabha Atomic Research Centre, India
Current Research in Drug Discovery, Volume 1, Issue 2, pp. 45–50 · doi.org/10.3844/crddsp.2014.45.50
Abstract
A series of novel 2,4 diamino-s-triazine was designed as potential Mycobacterium tuberculosis (Mtb) Dihydro folate reductase inhibitors. The synthesized compounds were evaluated in whole cells by employing Resazurin Microtitre Plate Assay (REMA) against Mtb H37Rv, using known DHFR inhibitors Methotrexate and Trimethoprim as standard drugs. The most active compound in the whole cell assay was selected for DHFR enzyme assay against the pathogen and human enzymes. The enzyme assay results revealed that this compound is a selective pathogenic DHFR inhibitor, with 13 fold more selectivity than Methotrexate. Thus, these derivatives have provided promising selective Hits/Leads as MTb DHFR inhibitors and can provide valuable information for further design of potent anti-TB drugs.
Licence and reuse
Open access. This article is licensed under a Creative Commons Attribution 3.0 Licence (CC BY 3.0), as printed on the article, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source. No permission is needed.
How to reuse this articleResponses (0)
About this article
Lele, A. C., Raju, A., Ray, M., Rajan, M. & Degani, M. S. (2014). Design and Synthesis of Diaminotriazines as Anti-Tuberculosis DHFR Inhibitors. Current Research in Drug Discovery, 1(2), 45–50. https://doi.org/10.3844/crddsp.2014.45.50
- Licence
- CC BY 3.0
- Issue
- Volume 1, Issue 2
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record